While LRP1 serves as a novel APOA4 receptor in adipose tissue for glucose homeostasis [387], it remains to be determined whether APOA4-LRP1 interactions in the intestine can similarly suppress inflammatory cytokine production and restrict the development of colitis or IBD [77]. Here, LRP1 is linked to irritable bowel syndrome.